News
04-30-2026, 01:22 PM
Immunotherapy has become a standard of care in treating high-risk, early-stage breast cancers, yet it has had limited success in shrinking tumors.
More... (https://www.news-medical.net/news/20260430/Liquid-biopsy-predicts-immune-response-in-high-risk-breast-cancer-patients.aspx)
More... (https://www.news-medical.net/news/20260430/Liquid-biopsy-predicts-immune-response-in-high-risk-breast-cancer-patients.aspx)